相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship
David Y. Graham et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay
Bea Van den Poel et al.
ACTA CLINICA BELGICA (2021)
European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners
David Y. Graham et al.
GUT (2021)
European Registry on Helicobacter pylori management (Hp--EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients
Olga P. Nyssen et al.
GUT (2021)
Vonoprazan-containingHelicobacter pyloritriple therapies contribution to global antimicrobial resistance
David Y. Graham et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Rifabutin for the Treatment of Helicobacter pylori Infection: A Review
Javier P. Gisbert
PATHOGENS (2021)
Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis
Theodore Rokkas et al.
GASTROENTEROLOGY (2021)
AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review
Shailja C. Shah et al.
GASTROENTEROLOGY (2021)
PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis
Cailing Li et al.
HELICOBACTER (2021)
Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori
Takahisa Furuta et al.
DIGESTION (2020)
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
Sho Suzuki et al.
GUT (2020)
Diagnostic Accuracy of a Noninvasive Test for Detection of Helicobacter pylori and Resistance to Clarithromycin in Stool by the Amplidiag H. pylori plus ClariR Real-Time PCR Assay
Maxime Pichon et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2020)
Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication A Double-Blind, Randomized, Controlled Trial
David Y. Graham et al.
ANNALS OF INTERNAL MEDICINE (2020)
PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis
Cai-Ping Gao et al.
HELICOBACTER (2020)
Evaluation of the Allplex™ H pylori and ClariR PCR Assay for Helicobacter pylori detection on gastric biopsies
Quentin Jehanne et al.
HELICOBACTER (2020)
Optimizing the MIC breakpoints of amoxicillin and tetracycline for antibiotic selection in the rescue therapy ofH. pyloriwith bismuth quadruple regimen
Ming-Tsung Hsieh et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Clinical impact of vonoprazan-based dual therapy with amoxicillin forH. pyloriinfection in a treatment-naive cohort of junior high school students in Japan
Takuji Gotoda et al.
JOURNAL OF GASTROENTEROLOGY (2020)
S1348 Triple Therapy for Primary Treatment of Helicobacter pylori: A 19-Year U.S. Single Center Experience
Brian D. Ginnebaugh et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus
Jyh-Ming Liou et al.
GUT (2020)
A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-lineHelicobacter pyloriinfection eradication: A randomized trial
Zhiqiang Song et al.
HELICOBACTER (2020)
Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial
Ira N. Kalfus et al.
ANTIBIOTICS-BASEL (2020)
Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship
David Y. Graham
ANTIBIOTICS-BASEL (2020)
Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in Helicobacter pylori
Konrad Egli et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
E-test versus agar dilution for antibiotic susceptibility testing of Helicobacter pylori: a comparison study
Muhammad Miftahussurur et al.
BMC RESEARCH NOTES (2020)
Migration and tuberculosis in Europe
D. A. Boudville et al.
JOURNAL OF CLINICAL TUBERCULOSIS AND OTHER MYCOBACTERIAL DISEASES (2020)
A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial
Wei-Chen Tai et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment
Qi Chen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes
Doron Boltin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice
Conghua Song et al.
HELICOBACTER (2019)
Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing
Daniel Pohl et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI
David Y. Graham et al.
HELICOBACTER (2019)
Molecular diagnosis of Helicobacter pylori infection in gastric biopsies: Evaluation of the Amplidiag® H-pylori plus ClariR assay
Constantin Hays et al.
HELICOBACTER (2019)
Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance
Julio Valle-Munoz et al.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS (2019)
Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens
Pablo Munoz-Gomez et al.
HELICOBACTER (2018)
Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency
David Y. Graham et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States
Hashem B. El-Serag et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Update on the Use of Vonoprazan: A Competitive Acid Blocker
David Y. Graham et al.
GASTROENTEROLOGY (2018)
Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases
Tadayuki Oshima et al.
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY (2018)
Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies
David Y. Graham et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China
Yong Xie et al.
HELICOBACTER (2018)
Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues
David Y. Graham
GUT (2017)
Illusions regarding Helicobacter pylori clinical trials and treatment guidelines
David Y. Graham
GUT (2017)
Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?
David Y. Graham et al.
SAUDI JOURNAL OF GASTROENTEROLOGY (2017)
A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance
Feng-Woei Tsay et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Furazolidone, an Underutilized Drug for H-pylori Eradication: Lessons from Iran
Marjan Mohammadi et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Hp-normogram (normo-graham) for Assessing the Outcome of H-pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype
David Y. Graham
HELICOBACTER (2016)
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy
Qi Chen et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use
Sun Gyo Lim et al.
DIGESTIVE AND LIVER DISEASE (2016)
Molecular mechanisms and clinical implications of bacterial persistence
Joran Elie Michiels et al.
DRUG RESISTANCE UPDATES (2016)
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
Kazunari Murakami et al.
GUT (2016)
Role of bismuth in improving Helicobacter pylori eradication with triple therapy
Maria Pina Dore et al.
GUT (2016)
Molecular detection of Helicobacter pylori antibiotic resistance in stool vs biopsy samples
Denise E. Brennan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans
Seiji Shiota et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg
Shu Sahara et al.
DIGESTION (2015)
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly
David Y. Graham et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2015)
Kyoto global consensus report on Helicobacter pylori gastritis
Kentaro Sugano et al.
GUT (2015)
Heteroresistance of Helicobacter pylori from the same patient prior to antibiotic treatment
Cheng-Yen Kao et al.
INFECTION GENETICS AND EVOLUTION (2014)
Efficacy of Bismuth-Containing Quadruple Therapies for Clarithromycin-, Metronidazole-, and Fluoroquinolone-Resistant Helicobacter pylori Infections in a Prospective Study
Xiao Liang et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption
Francis Megraud et al.
GUT (2013)
Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered?
C. A. M. McNulty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype
M. Sugimoto et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Adherence to Medications: Insights Arising from Studies on the Unreliable Link Between Prescribed and Actual Drug Dosing Histories
Terrence F. Blaschke et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Greater Than 95% Success with 14-day Bismuth Quadruple Anti-Helicobacter pylori Therapy: A Pilot Study in US Hispanics
Cesar O. Salazar et al.
HELICOBACTER (2012)
Helicobacter pylori molecular diagnosis
Philippe Lehours et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2011)
Helicobacter pylori Therapy Demystified
David Y. Graham et al.
HELICOBACTER (2011)
Comparative evaluation of synergy of combinations of β-lactams with fluoroquinolones or a macrolide in Streptococcus pneumoniae
L. Drago et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial
Peter Malfertheiner et al.
LANCET (2011)
Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection
Takahisa Furuta et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2010)
Helicobacter pylori treatment in the era of increasing antibiotic resistance
David Y. Graham et al.
GUT (2010)
Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States
David Y. Graham et al.
JOURNAL OF GASTROENTEROLOGY (2010)
Evaluation of a New Test, GenoType HelicoDR, for Molecular Detection of Antibiotic Resistance in Helicobacter pylori
Emmanuelle Cambau et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
African, Asian or Indian enigma, the East Asian Helicobacter pylori: facts or medical myths
David Y. Graham et al.
JOURNAL OF DIGESTIVE DISEASES (2009)
New concepts of resistance in the treatment of Helicobacter pylori infections
David Y. Graham et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2008)
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy
Naohito Shirai et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Meta-analysis:: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori
L. Fischbach et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Persister cells, dormancy and infectious disease
Kim Lewis
NATURE REVIEWS MICROBIOLOGY (2007)
DNA sequence analysis of rdxA and frxA from paired metronidazole-sensitive and -resistant Helicobacter pylori isolates obtained from patients with heteroresistance
MJ Matteo et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Drug therapy - Adherence to medication
L Osterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000
JH Li et al.
CLINICAL INFECTIOUS DISEASES (2005)
Meta-analysis:: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies
LA Fischbach et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status
M Sugimoto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections
BJ McMahon et al.
ANNALS OF INTERNAL MEDICINE (2003)
Management of Helicobacter pylori eradication -: the influence of structured counselling and follow-up
FA Al-Eidan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19
T Furuta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole
MJR Janssen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori
MS Osato et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2001)
The HOMER study:: The effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection
KD Bardhan et al.
HELICOBACTER (2000)
Pathogenesis of increased sucrose permeability in H-pylori gastritis
DY Graham
DIGESTIVE DISEASES AND SCIENCES (2000)
分享论文
